EU/3/19/2161

Table of contents

About

On 29 May 2019, orphan designation (EU/3/19/2161) was granted by the European Commission to Worphmed World Orphan Medicines Limited, United Kingdom, for diacerein for the treatment of epidermolysis bullosa.

Key facts

Active substance
Diacerein
Disease / condition
Treatment of epidermolysis bullosa
Date of first decision
29/05/2019
Outcome
Positive
EU designation number
EU/3/19/2161

Sponsor's contact details

Worphmed World Orphan Medicines Limited
1st Floor, Victory House
99-101 Regent Street
London W1B 4EZ
United Kingdom
Tel. +44 (0)20 3214 0442
E-mail: science@worphmed.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating